AI Article Synopsis
- The study investigated treatment outcomes for multidrug-resistant (MDR) and rifampicin-resistant tuberculosis (TB) in Central and West Africa, due to a lack of available data in these regions.
- Fourteen studies involving 4,268 individuals were analyzed, revealing a pooled treatment success rate of 80.8% in Central Africa and 69.2% in West Africa, which is higher than the WHO's global estimate of 59%.
- The findings suggest that shorter treatment regimens and standardized conditions may have led to improved outcomes, though the limited literature indicates a need for more comprehensive resources in these areas.
Article Abstract
Objectives: We aimed to investigate published data on treatment outcomes of multidrug-resistant (MDR)/rifampicin-resistant tuberculosis (TB) in Central and West Africa because these, to the best of our knowledge, are sparsely available.
Methods: Systematic review and meta-analysis.
Results: A total of 14 studies were included, representing 4268 individuals in 14 of the 26 countries. Using a random-effects model meta-analysis, we observed a pooled success rate of 80.8% (95% confidence interval [CI] 56.0-93.3) for the Central African subgroup and 69.2% (95% CI 56.3-79.7) for the West African subgroup (P = 0.0522). The overall treatment success for all studies was 74.6% (95% CI 65.0-82.2). We found high heterogeneity among included studies (I = 96.1%). The estimated proportion of successfully treated individuals with MDR/rifampicin-resistant TB was considerably higher than the global estimate provided by the World Health Organization (59%), reaching the 2015 World Health Organization target of at least 75% treatment success for MDR-TB.
Conclusion: The use of shorter treatment regimens and the standardized treatment conditions, including directly observed therapy in these studies, could have contributed to a high treatment success. Yet, the available literature was not fully representative of the regions, possibly highlighting the sparse resources in many of these countries. The review was registered at PROSPERO (https://www.crd.york.ac.uk/prospero/) (CRD42022353163).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2022.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementing brief behavioral treatment for insomnia in Department of Veterans Affairs Primary Care Mental Health Integration clinics: Reach outcomes from a hybrid type 3 effectiveness-implementation trial.
Psychol Serv
January 2025
Center for Health Equity Research and Promotion, Department of Veterans Affairs Pittsburgh Healthcare System.
Chronic insomnia is one of the most common health problems among veterans and can significantly impact health, function, and quality of life. Brief behavioral treatment for insomnia (BBTI), an adaptation of cognitive behavioral therapy for insomnia (CBT-I), was developed to help increase access to care outside of specialty settings. However, training providers alone is rarely sufficient, and implementation strategies are needed for successful uptake, adoption, and sustainable delivery of care.
View Article and Find Full Text PDFOsteochondral and chondral injuries of the patellofemoral joint are common in active patients, and effective management requires a thorough physical and imaging evaluation, a detailed understanding of the unique anatomic and biomechanical joint properties contributing to these injuries, and an appropriate selection of treatment modality. Diagnosis of patellofemoral chondral injuries can be challenging, and differentiating between various causes of anterior knee pain is crucial to successful outcomes. Once identified, nonsurgical treatments including physical therapy, bracing, and injections are a mainstay of initial management.
View Article and Find Full Text PDFIn the young, active patient with osteoarthritis, the optimal treatment of B2 glenoid morphology remains a subject of continued debate. Current treatment options have specific advantages and disadvantages. These treatments include hemiarthroplasty with or without glenoid reaming, total shoulder arthroplasty (TSA) with or without eccentric reaming, TSA with bone graft or posteriorly augmented glenoid implant, and reverse TSA.
View Article and Find Full Text PDFA knowledge, attitude and practices assessment of control measures for bovine tuberculosis and brucellosis towards a more effective approach to national control programs in South Africa.
Trop Anim Health Prod
January 2025
Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, Onderstepoort, University of Pretoria, Pretoria, South Africa.
Bovine brucellosis and bovine tuberculosis are zoonotic diseases with economic and public health importance across the world, especially in developing countries where the diseases are endemic. The diseases are classified as neglected diseases in developing nations with poor resources despite good control measures in some developed countries. The purpose of this study is to assess the knowledge, attitudes and perceptions (KAP) of stakeholders towards control measures for bovine brucellosis (BR) and bovine tuberculosis (bTB) at a livestock-wildlife interface.
View Article and Find Full Text PDFA standardized care pathway increases optimal dialysis starts.
Am J Manag Care
December 2024
Panoramic Health, 850 W Rio Salado Pkwy, Ste 201, Tempe, AZ 85281. Email:
Objective: To determine whether an intensive value-based care educational program that includes a standardized end-stage renal disease (ESRD) transition pathway would improve the number of optimal starts within Kidney Contracting Entities (KCEs).
Study Design: Retrospective cohort study.
Methods: We recorded optimal starts, defined as the initiation of dialysis without a central venous catheter, and the initial modality type (hemodialysis vs peritoneal dialysis [PD]) in adult Medicare patients in a Comprehensive Kidney Care Contracting program.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!